IDEAYA Biosciences, Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

IDEAYA Biosciences, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. Darovasertib Plus Crizotinib vs Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 Trial Marlana Orloff,1 Egle Ramelyte,2 Marcus O. Butler,3 Piotr Rutkowski,4 Lorenza Di Guardo,5 Matteo S.